|Assessment Status||Assessment Process Complete|
|Indication||For the management of multiple cardiovascular risks in overweight or obese patients in Ireland|
|NCPE assessment completed||01/06/2006|
In June 2006, Sanofi-Aventis submitted an evaluation of the cost-effectiveness of rimonabant (in addition to diet and exercise) in the management of multiple cardiovascular risks in overweight or obese patients in Ireland, to support its application for reimbursement of rimonabant under the Community Drugs Schemes. The following report was prepared by the National Centre for Pharmacoeconomics and submitted on request to the Department of Health and Children.